{
 "name": "Psychedelic and ketamine clinical trials with San Diego County sites",
 "description": "Registered clinical trials of psilocybin, MDMA, LSD, DMT, ketamine and related drugs that list a study site in San Diego County, with status, sponsor, phase and dates from ClinicalTrials.gov.",
 "publisher": "Magic Mushrooms San Diego",
 "url": "https://magicmushroomssandiego.com/psychedelic-clinical-trials-san-diego",
 "license": "CC BY 4.0",
 "license_url": "https://creativecommons.org/licenses/by/4.0/",
 "updated": "2026-10-21",
 "record_count": 45,
 "records": [
  {
   "group": "A",
   "nct": "NCT06524830",
   "title": "A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)",
   "acronym": null,
   "sponsor": "atai Therapeutics, Inc.",
   "phase": "PHASE2",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "VLS-01-203 BU",
    "VLS-01-BU Placebo"
   ],
   "status": "RECRUITING",
   "start": "2024-12-30",
   "primary_completion": "2026-08-01",
   "completion": "2026-08-30",
   "last_update": "2026-05-11",
   "enrollment": 142,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "A",
   "nct": "NCT06814522",
   "title": "Psilocybin-Assisted Therapy for Physician Well-Being and Burnout",
   "acronym": "PAT-B",
   "sponsor": "University of California, San Diego",
   "phase": "PHASE1, PHASE2",
   "conditions": [
    "Burnout",
    "Burnout, Healthcare Workers"
   ],
   "interventions": [
    "Psilocybin, [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate",
    "Real-time Biofeedback"
   ],
   "status": "RECRUITING",
   "start": "2025-01-13",
   "primary_completion": "2028-06",
   "completion": "2028-08",
   "last_update": "2026-09-02",
   "enrollment": 30,
   "results": false,
   "sd_sites": [
    "UC San Diego (San Diego)"
   ],
   "min_age": "21 Years",
   "max_age": "70 Years"
  },
  {
   "group": "A",
   "nct": "NCT07002034",
   "title": "RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses",
   "acronym": null,
   "sponsor": "Reunion Neuroscience Inc",
   "phase": "PHASE2",
   "conditions": [
    "Adjustment Disorder"
   ],
   "interventions": [
    "RE104 for Injection"
   ],
   "status": "RECRUITING",
   "start": "2025-07-30",
   "primary_completion": "2026-11",
   "completion": "2026-12",
   "last_update": "2026-09-15",
   "enrollment": 100,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "80 Years"
  },
  {
   "group": "A",
   "nct": "NCT07456696",
   "title": "An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)",
   "acronym": "EMPOWER-1",
   "sponsor": "Transcend Therapeutics",
   "phase": "PHASE3",
   "conditions": [
    "Post Traumatic Stress Disorder"
   ],
   "interventions": [
    "TSND-201",
    "Placebo"
   ],
   "status": "RECRUITING",
   "start": "2026-04-02",
   "primary_completion": "2027-12",
   "completion": "2027-12",
   "last_update": "2026-09-17",
   "enrollment": 300,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry (La Jolla)",
    "Excell Research (Oceanside)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT07489651",
   "title": "RE104 Safety and Efficacy Study in Generalized Anxiety Disorder",
   "acronym": null,
   "sponsor": "Reunion Neuroscience Inc",
   "phase": "PHASE2",
   "conditions": [
    "Generalized Anxiety Disorder"
   ],
   "interventions": [
    "RE104 for Injection",
    "Placebo"
   ],
   "status": "RECRUITING",
   "start": "2026-04-20",
   "primary_completion": "2027-07",
   "completion": "2027-09",
   "last_update": "2026-09-24",
   "enrollment": 160,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "A",
   "nct": "NCT07592689",
   "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)",
   "acronym": null,
   "sponsor": "Definium Therapeutics US, Inc.",
   "phase": "PHASE3",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "Placebo",
    "DT120"
   ],
   "status": "RECRUITING",
   "start": "2026-05-10",
   "primary_completion": "2027-09",
   "completion": "2028-06",
   "last_update": "2026-10-14",
   "enrollment": 165,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "A",
   "nct": "NCT07693257",
   "title": "Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)",
   "acronym": null,
   "sponsor": "Jon Dean",
   "phase": "PHASE1",
   "conditions": [
    "Healthy Participants Study"
   ],
   "interventions": [
    "N,N-Dimethyltryptamine (15 mg)",
    "N,N-Dimethyltryptamine (17.5 mg)"
   ],
   "status": "NOT_YET_RECRUITING",
   "start": "2026-09-01",
   "primary_completion": "2028-09-01",
   "completion": "2029-09-01",
   "last_update": "2026-07-09",
   "enrollment": 20,
   "results": false,
   "sd_sites": [
    "Altman Clinical and Translational Research Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "A",
   "nct": "NCT06605105",
   "title": "Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)",
   "acronym": "EXTEND",
   "sponsor": "Cybin IRL Limited",
   "phase": "PHASE3",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "CYB003"
   ],
   "status": "ENROLLING_BY_INVITATION",
   "start": "2025-07-18",
   "primary_completion": "2028-06-06",
   "completion": "2028-06-06",
   "last_update": "2026-09-25",
   "enrollment": 468,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "Excell Research, Inc (Oceanside)"
   ],
   "min_age": "18 Years",
   "max_age": "85 Years"
  },
  {
   "group": "A",
   "nct": "NCT05224336",
   "title": "Psilocybin-assisted Therapy for Phantom Limb Pain",
   "acronym": null,
   "sponsor": "University of California, San Diego",
   "phase": "PHASE1",
   "conditions": [
    "Phantom Limb Pain"
   ],
   "interventions": [
    "Psilocybin",
    "Placebo Niacin"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2022-10-03",
   "primary_completion": "2024-03-07",
   "completion": "2031-04-30",
   "last_update": "2026-10-09",
   "enrollment": 10,
   "results": false,
   "sd_sites": [
    "University of California, San Diego (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "75 Years"
  },
  {
   "group": "A",
   "nct": "NCT05711940",
   "title": "Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE3",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2023-02-14",
   "primary_completion": "2025-11-13",
   "completion": "2026-12",
   "last_update": "2026-08-10",
   "enrollment": 572,
   "results": false,
   "sd_sites": [
    "The Regents of the University of California - San Diego (La Jolla)",
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT05733546",
   "title": "A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE2",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2023-01-30",
   "primary_completion": "2025-09",
   "completion": "2025-09",
   "last_update": "2025-08-19",
   "enrollment": 102,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT06117306",
   "title": "MDMA-assisted Massed Prolonged Exposure for PTSD",
   "acronym": "MDMA-PE",
   "sponsor": "Healing Breakthrough",
   "phase": "PHASE3",
   "conditions": [
    "Post-Traumatic Stress Disorder"
   ],
   "interventions": [
    "3,4 Methylenedioxymethamphetamine",
    "Prolonged Exposure"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2024-10-25",
   "primary_completion": "2027-03",
   "completion": "2027-03",
   "last_update": "2026-08-26",
   "enrollment": 20,
   "results": false,
   "sd_sites": [
    "VA San Diego Healthcare System, San Diego, CA (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "64 Years"
  },
  {
   "group": "A",
   "nct": "NCT06308653",
   "title": "Psilocybin for Major Depressive Disorder (MDD)",
   "acronym": "uAspire",
   "sponsor": "Usona Institute",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Major"
   ],
   "interventions": [
    "Psilocybin 25 mg",
    "Inactive Placebo",
    "Psilocybin 5 mg",
    "Psychosocial Support"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2024-03-13",
   "primary_completion": "2026-01-05",
   "completion": "2027-01-30",
   "last_update": "2026-10-21",
   "enrollment": 238,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT06564818",
   "title": "\"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder\"",
   "acronym": "APPROACH",
   "sponsor": "Cybin IRL Limited",
   "phase": "PHASE3",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "CYB003",
    "Psychological Support",
    "Placebo"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2024-12-17",
   "primary_completion": "2026-09-04",
   "completion": "2026-10",
   "last_update": "2026-09-28",
   "enrollment": 220,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "Excell Research, Inc (Oceanside)"
   ],
   "min_age": "18 Years",
   "max_age": "85 Years"
  },
  {
   "group": "A",
   "nct": "NCT06741228",
   "title": "A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)",
   "acronym": null,
   "sponsor": "Definium Therapeutics US, Inc.",
   "phase": "PHASE3",
   "conditions": [
    "Generalized Anxiety Disorder"
   ],
   "interventions": [
    "Placebo",
    "DT120"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2024-12-11",
   "primary_completion": "2026-07-15",
   "completion": "2027-04",
   "last_update": "2026-09-25",
   "enrollment": 214,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "A",
   "nct": "NCT06941844",
   "title": "A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)",
   "acronym": null,
   "sponsor": "Definium Therapeutics US, Inc.",
   "phase": "PHASE3",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "Placebo",
    "DT120"
   ],
   "status": "ACTIVE_NOT_RECRUITING",
   "start": "2025-04-14",
   "primary_completion": "2026-05-20",
   "completion": "2027-02",
   "last_update": "2026-08-28",
   "enrollment": 149,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "A",
   "nct": "NCT03775200",
   "title": "The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression",
   "acronym": "P-TRD",
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE2",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "COMPLETED",
   "start": "2019-03-01",
   "primary_completion": "2021-07-30",
   "completion": "2021-09-27",
   "last_update": "2023-04-24",
   "enrollment": 233,
   "results": true,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "Altman Clinical and Translational Research Institute, University of California (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT04519957",
   "title": "Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "Observational",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [],
   "status": "COMPLETED",
   "start": "2020-07-20",
   "primary_completion": "2022-08-11",
   "completion": "2022-08-11",
   "last_update": "2022-09-22",
   "enrollment": 66,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "Altman Clinical and Translational Research Institute, University of California (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "55 Years"
  },
  {
   "group": "A",
   "nct": "NCT04661514",
   "title": "Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy",
   "acronym": null,
   "sponsor": "University of California, San Diego",
   "phase": "PHASE2",
   "conditions": [
    "Anorexia Nervosa"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "COMPLETED",
   "start": "2021-05-01",
   "primary_completion": "2022-03-10",
   "completion": "2022-06-10",
   "last_update": "2022-07-25",
   "enrollment": 16,
   "results": false,
   "sd_sites": [
    "Altman Clinical and Translational Research Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "40 Years"
  },
  {
   "group": "A",
   "nct": "NCT04739865",
   "title": "The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE2",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "COMPLETED",
   "start": "2020-08-10",
   "primary_completion": "2021-10-14",
   "completion": "2021-10-14",
   "last_update": "2023-11-09",
   "enrollment": 19,
   "results": true,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT05407064",
   "title": "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms",
   "acronym": null,
   "sponsor": "Definium Therapeutics US, Inc.",
   "phase": "PHASE2",
   "conditions": [
    "Anxiety Generalized"
   ],
   "interventions": [
    "MM120",
    "Placebo"
   ],
   "status": "COMPLETED",
   "start": "2022-08-24",
   "primary_completion": "2023-10-06",
   "completion": "2023-11-27",
   "last_update": "2026-02-27",
   "enrollment": 198,
   "results": true,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "A",
   "nct": "NCT05481736",
   "title": "Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE2",
   "conditions": [
    "Anorexia Nervosa"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "COMPLETED",
   "start": "2022-10-12",
   "primary_completion": "2024-11-18",
   "completion": "2024-11-18",
   "last_update": "2024-12-04",
   "enrollment": 32,
   "results": false,
   "sd_sites": [
    "Altman Clinical and Translational Research Institute (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT05624268",
   "title": "Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD",
   "acronym": null,
   "sponsor": "COMPASS Pathways",
   "phase": "PHASE3",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "Psilocybin"
   ],
   "status": "COMPLETED",
   "start": "2023-01-24",
   "primary_completion": "2025-05-28",
   "completion": "2026-04-15",
   "last_update": "2026-08-10",
   "enrollment": 258,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "University California San Diego (La Jolla)",
    "Artemis Institute for Clinical Research (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "A",
   "nct": "NCT05870540",
   "title": "BPL-003 Efficacy and Safety in Treatment Resistant Depression",
   "acronym": null,
   "sponsor": "Beckley Psytech Limited",
   "phase": "PHASE2",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "BPL-003",
    "BPL-003"
   ],
   "status": "COMPLETED",
   "start": "2023-09-14",
   "primary_completion": "2025-03-28",
   "completion": "2025-07-03",
   "last_update": "2026-09-10",
   "enrollment": 196,
   "results": true,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "75 Years"
  },
  {
   "group": "A",
   "nct": "NCT05979844",
   "title": "MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD",
   "acronym": "MDMA-bCBCT",
   "sponsor": "Dr. Leslie Morland",
   "phase": "PHASE3",
   "conditions": [
    "PTSD",
    "Relational Problems"
   ],
   "interventions": [
    "3,4-methylenedioxymethamphetamine (MDMA)",
    "Brief Cognitive Behavioral Conjoint Therapy (bCBCT)"
   ],
   "status": "COMPLETED",
   "start": "2023-10-06",
   "primary_completion": "2025-11-14",
   "completion": "2025-11-14",
   "last_update": "2025-12-08",
   "enrollment": 16,
   "results": false,
   "sd_sites": [
    "VA San Diego Healthcare System, San Diego, CA (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT07284667",
   "title": "ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response",
   "acronym": "NORLIGHT",
   "sponsor": "ACADIA Pharmaceuticals Inc.",
   "phase": "PHASE2",
   "conditions": [
    "Major Depressive Disorder (MDD)",
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "ACP-211",
    "Placebo"
   ],
   "status": "RECRUITING",
   "start": "2025-11-14",
   "primary_completion": "2027-08",
   "completion": "2027-09",
   "last_update": "2026-10-05",
   "enrollment": 153,
   "results": false,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT07716098",
   "title": "A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression",
   "acronym": null,
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "Esketamine 56 mg",
    "Esketamine 84 mg",
    "Placebo"
   ],
   "status": "RECRUITING",
   "start": "2026-07-23",
   "primary_completion": "2028-12-27",
   "completion": "2029-09-12",
   "last_update": "2026-09-25",
   "enrollment": 348,
   "results": false,
   "sd_sites": [
    "Artemis Institute for Clinical Research (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT07369089",
   "title": "Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement",
   "acronym": null,
   "sponsor": "University of California, San Diego",
   "phase": "PHASE2",
   "conditions": [
    "Opioid Use Disorder"
   ],
   "interventions": [
    "Ketamine",
    "Mindfulness-Oriented Recovery Enhancement (MORE)",
    "Support Group"
   ],
   "status": "NOT_YET_RECRUITING",
   "start": "2026-02",
   "primary_completion": "2028-01",
   "completion": "2028-04",
   "last_update": "2026-02-03",
   "enrollment": 88,
   "results": false,
   "sd_sites": [
    "University of California, San Diego (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT07396220",
   "title": "Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation",
   "acronym": "PIK-SI",
   "sponsor": "University of California, San Diego",
   "phase": "NA",
   "conditions": [
    "Suicidal Ideation"
   ],
   "interventions": [
    "Naturalistic Intranasal Esketamine",
    "Brief Cognitive Behavioral Therapy for Suicide Prevention"
   ],
   "status": "ENROLLING_BY_INVITATION",
   "start": "2026-01-09",
   "primary_completion": "2028-01",
   "completion": "2029-01",
   "last_update": "2026-02-09",
   "enrollment": 56,
   "results": false,
   "sd_sites": [
    "UC San Diego Health - 4S Ranch (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "70 Years"
  },
  {
   "group": "B",
   "nct": "NCT02133001",
   "title": "A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide",
   "acronym": null,
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE2",
   "conditions": [
    "Major Depressive Disorder"
   ],
   "interventions": [
    "Esketamine",
    "Placebo"
   ],
   "status": "COMPLETED",
   "start": "2014-05-23",
   "primary_completion": "2016-02-01",
   "completion": "2016-02-01",
   "last_update": "2025-04-29",
   "enrollment": 68,
   "results": true,
   "sd_sites": [
    "(facility not named) (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "64 Years"
  },
  {
   "group": "B",
   "nct": "NCT02417064",
   "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",
   "acronym": "TRANSFORM-1",
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Treatment-resistant Depression"
   ],
   "interventions": [
    "Esketamine",
    "Placebo",
    "Duloxetine (Oral Antidepressant)",
    "Escitalopram (Oral antidepressant)",
    "Sertraline (Oral Antidepressant)",
    "Venlafaxine Extended Release (XR) (Oral Antidepressant)"
   ],
   "status": "COMPLETED",
   "start": "2015-08-10",
   "primary_completion": "2018-02-20",
   "completion": "2018-02-20",
   "last_update": "2025-04-29",
   "enrollment": 346,
   "results": true,
   "sd_sites": [
    "(facility not named) (San Diego)",
    "(facility not named) (San Marcos)"
   ],
   "min_age": "18 Years",
   "max_age": "64 Years"
  },
  {
   "group": "B",
   "nct": "NCT02422186",
   "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",
   "acronym": "TRANSFORM-3",
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "Esketamine",
    "Placebo",
    "Duloxetine (Oral Antidepressant)",
    "Escitalopram (Oral Antidepressant)",
    "Sertraline (Oral Antidepressant)",
    "Venlafaxine Extended Release (XR) (New Antidepressant)"
   ],
   "status": "COMPLETED",
   "start": "2015-08-20",
   "primary_completion": "2017-08-10",
   "completion": "2017-08-10",
   "last_update": "2025-04-29",
   "enrollment": 139,
   "results": true,
   "sd_sites": [
    "(facility not named) (San Diego)"
   ],
   "min_age": "65 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT02493868",
   "title": "A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression",
   "acronym": "SUSTAIN-1",
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "Esketamine",
    "Placebo",
    "Duloxetine (Oral Antidepressant)",
    "Escitalopram (Oral antidepressant)",
    "Sertraline (Oral Antidepressant)",
    "Venlafaxine Extended Release (XR) (Oral Antidepressant)"
   ],
   "status": "COMPLETED",
   "start": "2015-10-01",
   "primary_completion": "2018-02-15",
   "completion": "2018-02-16",
   "last_update": "2025-04-29",
   "enrollment": 719,
   "results": true,
   "sd_sites": [
    "(facility not named) (San Diego)",
    "(facility not named) (San Marcos)"
   ],
   "min_age": "18 Years",
   "max_age": "64 Years"
  },
  {
   "group": "B",
   "nct": "NCT02782104",
   "title": "A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression",
   "acronym": "SUSTAIN-3",
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "Esketamine Nasal Spray"
   ],
   "status": "COMPLETED",
   "start": "2016-06-09",
   "primary_completion": "2022-12-30",
   "completion": "2022-12-30",
   "last_update": "2025-04-29",
   "enrollment": 1148,
   "results": true,
   "sd_sites": [
    "(facility not named) (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT03097133",
   "title": "54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide",
   "acronym": "Aspire II",
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE3",
   "conditions": [
    "Depressive Disorder, Major"
   ],
   "interventions": [
    "Esketamine",
    "Placebo",
    "Standard of Care"
   ],
   "status": "COMPLETED",
   "start": "2017-06-15",
   "primary_completion": "2019-04-11",
   "completion": "2019-04-11",
   "last_update": "2025-04-29",
   "enrollment": 230,
   "results": true,
   "sd_sites": [
    "University of California San Diego/Psychiatry (San Diego)",
    "Sharp Mesa Vista Hospital (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "64 Years"
  },
  {
   "group": "B",
   "nct": "NCT04103892",
   "title": "A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study",
   "acronym": null,
   "sponsor": "Clexio Biosciences Ltd.",
   "phase": "PHASE2",
   "conditions": [
    "Adjunctive Treatment of Major Depressive Disorder"
   ],
   "interventions": [
    "CLE-100",
    "placebo"
   ],
   "status": "COMPLETED",
   "start": "2019-09-05",
   "primary_completion": "2022-09-21",
   "completion": "2022-10-05",
   "last_update": "2025-10-14",
   "enrollment": 146,
   "results": true,
   "sd_sites": [
    "Clinical Site 113 (Oceanside)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT04599855",
   "title": "A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression",
   "acronym": null,
   "sponsor": "Janssen Research & Development, LLC",
   "phase": "PHASE4",
   "conditions": [
    "Depressive Disorder, Treatment-Resistant"
   ],
   "interventions": [
    "Esketamine 56 mg",
    "Esketamine 84 mg",
    "Placebo"
   ],
   "status": "COMPLETED",
   "start": "2020-11-04",
   "primary_completion": "2024-01-31",
   "completion": "2024-01-31",
   "last_update": "2025-04-25",
   "enrollment": 477,
   "results": true,
   "sd_sites": [
    "University of California at San Diego (San Diego)",
    "Artemis Institute for Clinical Research (San Diego)",
    "CMB Clinical Trials (Santee)"
   ],
   "min_age": "18 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT04669665",
   "title": "A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide",
   "acronym": null,
   "sponsor": "Seelos Therapeutics, Inc.",
   "phase": "PHASE2",
   "conditions": [
    "Depressive Disorder, Major",
    "Suicidal"
   ],
   "interventions": [
    "SLS-002",
    "Placebo",
    "Standard of care",
    "Intranasal device"
   ],
   "status": "COMPLETED",
   "start": "2020-12-17",
   "primary_completion": "2023-06-17",
   "completion": "2023-07-14",
   "last_update": "2023-09-28",
   "enrollment": 164,
   "results": false,
   "sd_sites": [
    "Seelos Investigational Site (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT05414422",
   "title": "A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD",
   "acronym": null,
   "sponsor": "Perception Neuroscience",
   "phase": "PHASE2",
   "conditions": [
    "Treatment Resistant Depression"
   ],
   "interventions": [
    "PCN-101",
    "Placebo"
   ],
   "status": "COMPLETED",
   "start": "2022-02-01",
   "primary_completion": "2022-11-10",
   "completion": "2022-11-10",
   "last_update": "2024-06-04",
   "enrollment": 102,
   "results": true,
   "sd_sites": [
    "Kadima Neuropsychiatry Institute (La Jolla)",
    "Synergy San Diego (Lemon Grove)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT05604794",
   "title": "A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health",
   "acronym": null,
   "sponsor": "Field Trip Health",
   "phase": "PHASE4",
   "conditions": [
    "Depression",
    "Anxiety",
    "Post Traumatic Stress Disorder"
   ],
   "interventions": [
    "Ketamine-Assisted Psychotherapy (KAP)"
   ],
   "status": "COMPLETED",
   "start": "2020-03-13",
   "primary_completion": "2022-06-16",
   "completion": "2022-06-16",
   "last_update": "2024-03-20",
   "enrollment": 1806,
   "results": true,
   "sd_sites": [
    "San Diego Centre (San Diego)"
   ],
   "min_age": "19 Years",
   "max_age": null
  },
  {
   "group": "B",
   "nct": "NCT06340958",
   "title": "A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder",
   "acronym": "SOLEO",
   "sponsor": "Clexio Biosciences Ltd.",
   "phase": "PHASE2",
   "conditions": [
    "Adjunctive Treatment of Major Depressive Disorder (MDD)"
   ],
   "interventions": [
    "CLE-100",
    "Placebo"
   ],
   "status": "COMPLETED",
   "start": "2024-03-18",
   "primary_completion": "2025-06-06",
   "completion": "2025-11-25",
   "last_update": "2026-06-23",
   "enrollment": 99,
   "results": true,
   "sd_sites": [
    "Clinical Site 139 (La Jolla)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT02378415",
   "title": "Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression",
   "acronym": null,
   "sponsor": "United States Naval Medical Center, San Diego",
   "phase": "PHASE1",
   "conditions": [
    "Acute Depression"
   ],
   "interventions": [
    "Ketamine",
    "Placebo"
   ],
   "status": "TERMINATED",
   "start": "2011-12",
   "primary_completion": "2013-06",
   "completion": "2013-06",
   "last_update": "2015-03-04",
   "enrollment": 20,
   "results": false,
   "sd_sites": [
    "Naval Medical Center San Diego (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT02418702",
   "title": "A Study to Decrease Suicidal Thinking Using Ketamine",
   "acronym": null,
   "sponsor": "United States Naval Medical Center, San Diego",
   "phase": "PHASE3",
   "conditions": [
    "Depression",
    "Suicide"
   ],
   "interventions": [
    "0.2 mg/kg ketamine",
    "placebo"
   ],
   "status": "WITHDRAWN",
   "start": "2016-08",
   "primary_completion": "2016-08",
   "completion": "2017-08",
   "last_update": "2019-09-03",
   "enrollment": 0,
   "results": false,
   "sd_sites": [
    "Naval Medical Center San Diego (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "65 Years"
  },
  {
   "group": "B",
   "nct": "NCT05554627",
   "title": "VA Aripiprazole vs Esketamine for Treatment Resistant Depression",
   "acronym": "VAST-D II",
   "sponsor": "VA Office of Research and Development",
   "phase": "PHASE4",
   "conditions": [
    "Depressive Disorder, Major"
   ],
   "interventions": [
    "Esketamine",
    "Aripiprazole"
   ],
   "status": "WITHDRAWN",
   "start": "2023-10-27",
   "primary_completion": "2023-10-27",
   "completion": "2023-10-27",
   "last_update": "2024-01-05",
   "enrollment": 0,
   "results": false,
   "sd_sites": [
    "VA San Diego Healthcare System, San Diego, CA (San Diego)"
   ],
   "min_age": "18 Years",
   "max_age": "74 Years"
  },
  {
   "group": "B",
   "nct": "NCT05217706",
   "title": "Low-Dose Intravenous Ketamine for Adolescents With Depression and Suicidal Ideation in the Emergency Department",
   "acronym": null,
   "sponsor": "Rady Children's Hospital, San Diego",
   "phase": "EARLY_PHASE1",
   "conditions": [
    "Depression",
    "Suicidal Ideation"
   ],
   "interventions": [
    "Ketamine",
    "normal Saline"
   ],
   "status": "UNKNOWN",
   "start": "2022-03-01",
   "primary_completion": "2024-01-01",
   "completion": "2024-01-01",
   "last_update": "2023-02-16",
   "enrollment": 30,
   "results": false,
   "sd_sites": [
    "Rady Children's Hospital San Diego (San Diego)"
   ],
   "min_age": "12 Years",
   "max_age": "18 Years"
  }
 ],
 "source_note": "Records from ClinicalTrials.gov, the U.S. National Library of Medicine registry."
}